To compare two different routes of intermittently administered rhIL-2 with a highly active antiretroviral regimen to highly active antiretroviral therapy alone with respect to the proportion of subjects achieving greater than or equal to 50% increase in CD4 counts above prerandomization baseline values after one year of rhIL-2 and the rate of change in CD4 counts. This study will compare the safety, tolerance, and effect on quality of life of these regimens.
Showing the most recent 10 out of 1085 publications